RGD Reference Report - SRC kinase and mitogen-activated protein kinases in the progression from normal to malignant endometrium. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

SRC kinase and mitogen-activated protein kinases in the progression from normal to malignant endometrium.

Authors: Desouki, Mohamed Mokhtar  Rowan, Brian G 
Citation: Desouki MM and Rowan BG, Clin Cancer Res. 2004 Jan 15;10(2):546-55.
RGD ID: 13703137
Pubmed: PMID:14760076   (View Abstract at PubMed)


PURPOSE: The purpose of this research was to determine whether a correlation exists between the levels of activated mitogen-activated protein kinase (MAPK) and Src kinases and the progression from normal to malignant endometrium.
EXPERIMENTAL DESIGN: We measured total and phosphorylated levels for extracellular signal-regulated kinase 1/2, p38, stress-activated protein kinase/c-Jun NH(2)-terminal kinase, and Src kinases from 33 frozen endometrial adenocarcinomas and 38 benign endometrial specimens by quantitation of signals from Western blots using antibodies against these kinases.
RESULTS: Elevated phospho-extracellular signal-regulated kinase 1/2 (150 +/- 40 versus 46 +/- 7; P = 0.03), phospho-Src (28 +/- 5 versus 4 +/- 1), and phospho-p38 (131 +/- 16 versus 27 +/- 7; P < 0.001) was detected in benign versus malignant endometrium when the Western blot signal of activated kinase was normalized to total kinase levels and beta actin. A modest increase in active c-Jun NH(2)-terminal kinase was detected in carcinoma versus benign specimens (51 +/- 13 versus 43 +/- 10; P = 0.8). Expression of total kinases (normalized to beta-actin) was higher in carcinoma versus benign specimens, respectively (extracellular signal-regulated kinase 1/2, 9 +/- 2 versus 0.7 +/- 0.1; Src, 7 +/- 2 versus 0.4 +/- 0.1; stress-activated protein kinase c-Jun NH(2)-terminal kinase, 2 +/- 0.4 versus 0.2 +/- 0.02; P < 0.001; and p38, 1 +/- 0.2 versus 0.4 +/- 0.1; P < 0.01). Immunohistochemistry for active and total Src kinases and MAPKs detected positive staining in epithelial and stroma cells.
CONCLUSIONS: These data demonstrated that, in contrast with breast cancer, the progression from normal to malignant endometrium is not associated with activation of MAPK and Src kinases. Elevation of these active kinases in benign endometrium may contribute to endometrial resistance to the antiestrogen action of tamoxifen.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
endometrial adenocarcinoma  IEP 13703137; 13703137protein:decreased phosphorylation:endometrium (human)RGD 
endometrial adenocarcinoma  ISOMAPK1 (Homo sapiens)13703137; 13703137protein:decreased phosphorylation:endometrium (human)RGD 
endometrial adenocarcinoma  ISOMAPK3 (Homo sapiens)13703137; 13703137protein:decreased phosphorylation:endometrium (human)RGD 

Objects Annotated

Genes (Rattus norvegicus)
Mapk1  (mitogen activated protein kinase 1)
Mapk3  (mitogen activated protein kinase 3)

Genes (Mus musculus)
Mapk1  (mitogen-activated protein kinase 1)
Mapk3  (mitogen-activated protein kinase 3)

Genes (Homo sapiens)
MAPK1  (mitogen-activated protein kinase 1)
MAPK3  (mitogen-activated protein kinase 3)


Additional Information